Search Results
Your search for Staff matches 6670 pages
Showing 5751 - 5800CheckMate 227: Nivolumab Plus Ipilimumab Presents Another Option in First-Line Treatment of Advanced Non–Small Cell Lung Cancer
The combination of nivolumab and ipilimumab improved overall survival compared with chemotherapy as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) expression of at least 1%, according to the results of CheckMate 227....
Expert Point of View: Pilar Garrido, MD, PhD
At a press conference at the ESMO Congress 2019, Pilar Garrido, MD, PhD, of Ramon y Cajal University Hospital, Madrid, commented on the FLAURA trial: “These results are good news for patients with lung cancer, which is the most common cause of cancer deaths. Advances in the understanding of the...
Osimertinib Improves Overall Survival vs Gefitinib, Erlotinib in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: FLAURA Phase III Trial
The third-generation tyrosine kinase inhibitor osimertinib extended overall survival compared with the older tyrosine kinase inhibitors gefitinib and erlotinib in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to late-breaking final overall survival results of the ...
Expert Point of View: Nicoletta Colombo, MD
The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies...
Checkpoint Inhibitors Benefit Women With Advanced Stages of Cervical, Endometrial Cancers
Immunotherapy studies reported at the ESMO Congress 2019 yielded encouraging outcomes in patients with advanced cervical cancer that is microsatellite-stable and patients previously treated for advanced endometrial cancer. The combination of nivolumab and ipilimumab, with two different dosing...
Phase III Trials Suggest Paradigm Shift With PARP Inhibitors in Ovarian Cancer
At the ESMO Congress 2019, ovarian cancer was a topic of heightened interest, particularly due to findings reported in several important phase III studies of PARP inhibitors in front-line maintenance therapy for patients with newly diagnosed advanced disease—and not just those with BRCA mutations....
Neoadjuvant Immunotherapy Plus Chemotherapy Active in Women With Early Triple-Negative Breast Cancer
Immunotherapy has changed the treatment paradigms for melanoma, lung cancer, bladder cancer, and renal cancer. Now, checkpoint inhibitor therapy is making inroads in triple-negative breast cancer—one of the most difficult-to-treat aggressive types of breast cancer. Late-breaking results of the...
MONALEESA-3, MONARCH 2: CDK4/6 Inhibitors Plus Fulvestrant Benefit Survival in Advanced Breast Cancer
CDK4/6 inhibitors improve overall survival in advanced breast cancer, according to results of two important phase III trials reported at the ESMO Congress 2019. Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles Women’s Cancer Research Program, presented the findings from the...
ESMO Congress 2019 Offers a Global Stage for Important Clinical Data
The European Society for Medical Oncology (ESMO) Congress 2019, held September 27 to October 1 in Barcelona, welcomed clinicians, researchers, journalists, and exhibitors from around the world to hear advances across the oncology spectrum, in both clinical medicine and basic research. For this...
Financial Burdens of Patients With Cirrhosis and Impact on Screening for HCC
Data from a new study presented by Singal et al at The Liver Meeting found that patients with cirrhosis in the United States have substantial financial burden and this is associated with underuse of surveillance for hepatocellular carcinoma (HCC) (Abstract 201). Improved intervention strategies are ...
Short-Term Survival in Patients Aged 85 Years and Older After Colorectal Cancer Surgery
Results from a preliminary research study showed the majority of patients aged 85 years and older were still alive in the short-term after undergoing segmental colectomy for stage II and III colon cancer. Kaur et al presented these findings at the American College of Surgeons Clinical Congress...
UNC Health Care Introduces New Blood Research Center
The University of North Carolina (UNC) Department of Medicine recently announced the formation of the new UNC Blood Research Center, administratively housed within the Division of Hematology and Oncology. Nigel Key, MD, the Harold R. Roberts Distinguished Professor of Medicine, Pathology and...
Cleveland Clinic Names Halle Moore, MD, Director of Breast Medical Oncology, Adds New Staff Physicians
Halle Moore, MD, has been named Director of Breast Medical Oncology and Co-Director for the Comprehensive Breast Cancer Program at Cleveland Clinic. She will start her role in January 2020. Dr. Moore joined Cleveland Clinic in 1999 and specializes in the medical management of breast cancer. Her...
ASTRO and ACR Update Practice Parameters for Radiation Therapies
The American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR) recently released seven updated practice parameters for medical providers who use radiation therapy to treat patients with cancer. The updated practice parameters synthesize the clinical best practices...
Barry Paul Sleckman, MD, PhD, to Lead O’Neal Comprehensive Cancer Center
Barry Paul Sleckman, MD, PhD, a well-known cancer researcher who focuses on understanding how DNA double-strand breaks are generated and repaired—a key topic for cancer and immune system development and function—has been named Director of the O’Neal Comprehensive Cancer Center at the University of ...
The Oncology Care Model and Quality of Care: Defining, Measuring, and Implementing New Approaches to Cancer Care
The Oncology Care Model was instituted in 2016 by the Center for Medicare & Medicaid Innovation as a move away from the fee-for-service payment model and toward value-based care. It has sparked discussion ever since. How should quality be defined? Whose and what values should it reflect? How...
AACR Project GENIE Begins 5-Year Collaborative Research Project With $36 Million in New Funding
The American Association for Cancer Research (AACR) initiative known as AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) is launching a 5-year, $36 million research collaboration with a coalition of nine biopharmaceutical companies. The goal of the project is to obtain clinical ...
Remembering Craig Alguire
It is with great sadness that we report Craig Alguire, MD, 42, died on October 11, 2019, at his home in Grand Rapids, Michigan. Diagnosed with grade 4 glioblastoma multiforme in 2015, Dr. Alguire chronicled the effects the cancer was having on his life in his Patient’s Corner column, published in...
Robert Winn, MD, Named Director of VCU Massey Cancer Center
Robert Winn, MD, has been named Director of Virginia Commonwealth University Massey Cancer Center (VCU). An expert in lung cancer and community-based health care, Dr. Winn will start at VCU in December. Dr. Winn comes to VCU from the University of Illinois at Chicago, where he has served as...
Kazuaki Takabe, MD, PhD, FACS, Delivered Keynote on Immunotherapy for Breast Cancer at JSCO Meeting
Roswell Park Comprehensive Cancer Center’s Chief of Breast Surgery, Kazuaki Takabe, MD, PhD, FACS, delivered the keynote address on immunotherapy for breast cancer at the 57th Annual Meeting of the Japan Society of Clinical Oncology (JSCO) in Fukuoka. During the meeting, Dr. Takabe also led a...
FDA Awards Research Grants for the Study of Rare Cancers
The U.S. Food and Drug Administration (FDA) recently awarded 12 new clinical trial research grants totaling more than $15 million over the next 4 years, many of them focusing on cancer. Also, the FDA awarded two new research grants for natural history studies in rare diseases, totaling more than...
ASCO Presidents Through the Years: Past, Present, and Future
2020–2021: Lori J. Pierce, MD, FASTRO 2019–2020: Howard “Skip” Burris, III, MD, FACP 2018–2019: Monica M. Bertagnolli, MD 2017–2018: Bruce E. Johnson, MD 2016–2017: Daniel F. Hayes, MD 2015–2016: Julie Vose, MD, MBA 2014–2015: Peter P. Yu, MD 2013–2014: Clifford A. Hudis, MD 2012–2013: Sandra M....
FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia
On November 8, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions. Beta thalassemia is a blood disorder that reduces the production of hemoglobin. In...
2019 NCRI: Higher IGF-1 and Free Testosterone Levels May be Risk Factors for Prostate Cancer
Men with higher levels of free (biologically active) testosterone and insulin-like growth factor-1 (IGF-1) in their blood are more likely to be diagnosed with prostate cancer, according to research presented by Travis et al at the 2019 National Cancer Research Institute (NCRI) Cancer Conference....
2019 NCRI: CA125 Testing May Help General Practitioners to Detect Ovarian Cancer
Testing for levels of the serum biomarker cancer antigen 125 (CA125) in the blood may be a useful tool for the detection of ovarian cancer, and could help detect other types of cancer among patients in primary care, according to research presented by Funston et al at the 2019 National Cancer...
2019 NCRI: Hepatocellular Carcinoma Incidence and Mortality Rates in England Have Tripled Over the Past 20 Years
From 1997 to 2016, incidence and deaths from hepatocellular carcinoma have tripled in England, according to research presented by Burton et al at the 2019 National Cancer Research Institute (NCRI) Cancer Conference. Anya Burton, PhD, a cancer epidemiologist at Public Health England, said in a press ...
2019 NCRI: Use of Mendelian Randomization to Determine Role of Human Gut Microbiome in Colorectal Cancer Development
A study using a technique called Mendelian randomization to investigate the causal role played by bacteria in the development of colorectal cancer was presented at the 2019 National Cancer Research Institute (NCRI) Cancer Conference. First study author Kaitlin Wade, PhD, of the University of...
Thomas J. Smith, MD, Honored With ASCO’s Palliative and Supportive Care in Oncology Endowed Award and Lecture
ASCO recognized Thomas J. Smith, MD, FACP, FASCO, FAAHPM, a leader in the field of oncology palliative care, with its Walther Cancer Foundation Palliative and Supportive Care in Oncology Endowed Award and Lecture. Dr. Smith accepted his award and delivered a keynote address at the 2019 Supportive...
Daratumumab Combination Therapy for Patients With Multiple Myeloma Who Are Eligible for Transplantation
On September 26, 2019, daratumu-mab (Darzalex) was approved in combination with bortezomib, thalidomide, and dexamethasone for the treatment of multiple myeloma in newly diagnosed adult patients eligible for autologous stem cell transplantation (ASCT).1,2 Supporting Efficacy Data Approval was based ...
ASTRO Honors 2019 Gold Medalists, Honorary Member, and Other Award Recipients
The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2019 Gold Medal awards and other high-profile honors at the 2019ASTRO Annual Meeting. Gold Medalists and Honorary Member Walter J. Curran, Jr, MD;Silvia C. Formenti, MD, FASTRO; and Thomas R. Mackie, PhD, were...
LEAD Conference Awards 2019 Woman Oncologist of the Year
Claire Verschraegen, MD, was named the 2019 Woman Oncologist of the Year, and Shikha Jain, MD, FACP, received the 2019 Rising Star award at the first-ever Leadership Empowerment and Development: Enriching Experiences for Women in Hematology and Oncology (LEAD) Conference, hosted by Bio Ascend. An ...
Nearly One-Quarter of Completed Lung Cancer Clinical Trials Remain Unpublished
A new analysis has found that the results of up to one-fourth of completed lung cancer clinical trials are not published. This finding was published in a research letter by Al-Shbool et al in JAMA Network Open. “It is surprising to see that a quarter of trials that have been completed end up not...
Studies Report Efficacy of Proton Radiotherapy for Hepatocellular Carcinoma
Two new studies published in the International Journal of Radiation Oncology • Biology • Physics focused on the use of proton radiation therapy to treat patients with hepatocellular carcinoma. The first study, by Sanford et al, found that proton radiation may extend overall survival compared to...
Ravi Thadhani, MD, MPH, Named Chief Academic Officer at Partners HealthCare
Ravi Thadhani, MD, MPH, was named Chief Academic Officer at Partners HealthCare, starting November 11, 2019. Dr. Thadhani most recently served as Vice Dean of Research and Graduate Research Education at Cedars-Sinai Medical Center in Los Angeles. Prior to that, he served as Associate Director of...
ACCC Honors Seven Cancer Programs With Innovator Awards
ACCC Honors Seven Cancer Programs With Innovator Awards The Association of Community Cancer Centers (ACCC) honored the recipients of 2019 ACCC Innovator Awards at the ACCC 36th National Oncology Conference, October 30–November 1 in Orlando, Florida, where this year’s honorees shared innovative...
FDA Office of Hematology Oncology Products Reorganizes, Renamed Office of Oncologic Diseases
As part of modernization plans approved in September 2019, the U.S. Food and Drug Administration (FDA) office responsible for reviewing applications for new and existing cancer therapies has reorganized and been renamed. The Center for Drug Evaluation and Research (CDER) Office of Hematology and...
American College of Physicians Issues Guidance on Colorectal Cancer Screening for Average-Risk, Asymptomatic Adults Aged 50 to 75 Years
The American College of Physicians has issued a new guidance statement on colorectal cancer screening, which recommends screening for average-risk adults who do not have symptoms and are between the ages of 50 and 75 years. The guidelines were published by Qaseem et al in Annals of Internal...
Study Finds Nearly One in Four Oncologists Rarely or Never Mention Cost When Discussing Genomic Testing
Nearly one in four oncologists report rarely or never discussing the costs of genomic testing with their patients, according to a new study led by American Cancer Society investigators. The study, published by Yabroff et al in the Journal of the National Cancer Institute, found that oncologists...
FDA Approves Pegfilgrastim Biosimilar
On November 5, the U.S. Food and Drug Administration (FDA) approved a biosimilar to pegfilgrastim, pegfilgrastim-bmez (Ziextenzo). Pegfilgrastim-bmez is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving...
2019 Annual Meeting of the American Thyroid Association Briefs
The American Thyroid Association held its 2019 Annual Meeting from October 30 to November 3 in Chicago. Below are brief summaries of important oral presentations on thyroid cancer from the meeting. Incidence and Incidence-Based Mortality in a State Results of a retrospective analysis of thyroid...
Stephen Hahn, MD, to Be Nominated FDA Commissioner
In a press release issued by the White House today, President Donald J. Trump announced his intention to nominate Stephen Hahn, MD, FASTRO, to be the Commissioner of Food and Drugs at the Department of Health and Human Services. Dr. Hahn has been Chief Medical Executive at The University of Texas...
AACR-NCI-EORTC: Investigational KRAS G12C Inhibitor for KRAS-Mutant Solid Tumors
The investigational KRAS G12C inhibitor MRTX849 yielded clinical responses in patients with non–small cell lung cancer (NSCLC) and colorectal cancer harboring KRAS G12C mutations, according to data from a phase I clinical trial presented at the AACR-NCI-EORTC International Conference on Molecular...
AACR-NCI-EORTC: Selumetinib for Adult Patients With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
The investigational MEK inhibitor selumetinib showed clinical activity in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, according to preliminary results from an ongoing phase II study presented at the AACR-NCI-EORTC International Conference on Molecular...
First Survivor Views Survey Highlights Barriers to Addressing Side Effects of Cancer Treatment
Barriers to accessing appropriate therapies to address the physical and psychological side effects of cancer treatment continue to persist for patients and survivors, according to results of the Survivor Views survey conducted by the American Cancer Society Cancer Action Network (ACS CAN)....
Contrast-Enhanced Ultrasound May Help to Predict Cirrhotic Nodule Transformation to Hepatocellular Carcinoma
An article published by Lin et al in the American Journal of Roentgenology has identified sonographic biomarkers that may predict eventual malignant transformation of pathologically confirmed cirrhotic nodules for patients at risk for hepatocellular carcinoma. Lead investigator Manxia Lin, MD, of...
Palliative Care Bill Unanimously Approved by U.S. House of Representatives
On October 28, the U.S. House of Representatives unanimously approved the Palliative Care and Hospice Education and Training Act (PCHETA). The bipartisan bill would increase federal research funding for palliative care—including pain and symptom management—and would establish palliative care...
ASCO National Cancer Opinion Survey: Cancer Prevention, E-Cigarette, and End-of-Life Knowledge Gaps Reported
One in four Americans say they incorporate cancer prevention into their daily lives, according to ASCO’s third annual National Cancer Opinion Survey, despite research showing that as many as half of all cancer cases are preventable. The survey found low levels of awareness of known cancer risk...
Global Burden of Pancreatic Cancer From 1990–2017
The incidence and mortality rates of pancreatic cancer have increased in 195 countries and territories over a 27-year period, according to a systematic analysis performed within the Global Burden of Disease Study 2017 and published in The Lancet Gastroenterology & Hepatology. The study is the...
Top Research From 2019 Quality Care Symposium Focuses on Cost of Cancer Care, Patient Participation in Clinical Trials
The 2019 Quality Care Symposium took place September 6–7, 2019, in San Diego. Abstracts presented at the symposium focused on efforts to improve the quality of care for patients with cancer. Highlights from this year’s meeting included research on the cost of care and patient participation in...
ASCO’s Journal of Global Oncology Informs Cancer Care Everywhere
As part of ASCO’s commitment to improving cancer care delivery and outcomes around the world, it publishes the Journal of Global Oncology (JGO). JGO Editorial Board member Lawrence N. Shulman, MD, has been a proponent of global thinking and global action in cancer care throughout his career. Dr....
